KHCC Achieves Breakthrough In Cancer Treatment Using Modified T-Lymphocytes
KHCC announces breakthrough in cancer treatment using lab-engineered T-lymphocytes (CAR-T) for blood cancer patients, supported by a state-of-the-art GMP facility. This pioneering immunotherapy increases chances of eradicating tumors and reduces relapse rates, positioning KHCC as a global leader in advanced cancer treatment.
Reference News
KHCC Achieves Breakthrough In Cancer Treatment Using Modified T-Lymphocytes
KHCC announces breakthrough in cancer treatment using lab-engineered T-lymphocytes (CAR-T) for blood cancer patients, supported by a state-of-the-art GMP facility. This pioneering immunotherapy increases chances of eradicating tumors and reduces relapse rates, positioning KHCC as a global leader in advanced cancer treatment.